Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Cash & Equivalents: 2023-2025

Historic Cash & Equivalents for Upstream Bio (UPB) over the last 2 years, with Sep 2025 value amounting to $72.2 million.

  • Upstream Bio's Cash & Equivalents rose 119.02% to $72.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.2 million, marking a year-over-year increase of 119.02%. This contributed to the annual value of $325.9 million for FY2024, which is 1161.53% up from last year.
  • Latest data reveals that Upstream Bio reported Cash & Equivalents of $72.2 million as of Q3 2025, which was up 58.75% from $45.5 million recorded in Q2 2025.
  • In the past 5 years, Upstream Bio's Cash & Equivalents registered a high of $325.9 million during Q4 2024, and its lowest value of $25.8 million during Q4 2023.
  • For the 3-year period, Upstream Bio's Cash & Equivalents averaged around $77.8 million, with its median value being $47.3 million (2023).
  • Data for Upstream Bio's Cash & Equivalents shows a peak YoY increase of 1,161.53% (in 2024) and a maximum YoY decrease of 30.37% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Upstream Bio's Cash & Equivalents stood at $25.8 million in 2023, then skyrocketed by 1,161.53% to $325.9 million in 2024, then soared by 119.02% to $72.2 million in 2025.
  • Its Cash & Equivalents stands at $72.2 million for Q3 2025, versus $45.5 million for Q2 2025 and $71.3 million for Q1 2025.